<?xml version="1.0"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?>
  <?DTDIdentifier.IdentifierType public?>
  <?SourceDTD.DTDName journalpublishing.dtd?>
  <?SourceDTD.Version 2.3?>
  <?ConverterInfo.XSLTName jp2nlmx2.xsl?>
  <?ConverterInfo.Version 2?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Clin Trials</journal-id>
      <journal-id journal-id-type="publisher-id">CTJ</journal-id>
      <journal-id journal-id-type="hwp">spctj</journal-id>
      <journal-title-group>
        <journal-title>Clinical Trials (London, England)</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1740-7745</issn>
      <issn pub-type="epub">1740-7753</issn>
      <publisher>
        <publisher-name>SAGE Publications</publisher-name>
        <publisher-loc>UK</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmc">3131117</article-id>
      <article-id pub-id-type="pmid">20817650</article-id>
      <article-id pub-id-type="doi">10.1177/1740774510382439</article-id>
      <article-id pub-id-type="publisher-id">10.1177_1740774510382439</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Estimating causal effects using prior information on nontrial
                    treatments</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Bond</surname>
            <given-names>Simon J</given-names>
          </name>
          <xref ref-type="aff" rid="aff1-1740774510382439">a</xref>
          <xref ref-type="aff" rid="aff2-1740774510382439">b</xref>
          <xref ref-type="aff" rid="aff3-1740774510382439">c</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>White</surname>
            <given-names>Ian R</given-names>
          </name>
          <xref ref-type="aff" rid="aff1-1740774510382439">a</xref>
          <xref ref-type="corresp" rid="corresp1-1740774510382439"/>
        </contrib>
      </contrib-group>
      <aff id="aff1-1740774510382439"><label>a</label>MRC Biostatistics Unit, Institute of
                Public Health, Cambridge, UK</aff>
      <aff id="aff2-1740774510382439"><label>b</label>Mundipharma Research, Cambridge,
                UK</aff>
      <aff id="aff3-1740774510382439"><label>c</label>Cambridge Cancer Trials Centre and
                Cambridge Biomedical Research, Cambridge, UK</aff>
      <author-notes>
        <corresp id="corresp1-1740774510382439">Ian White, MRC Biostatistics Unit, Forvie
                    Site, Robinson Way, Cambridge, CB2 0SR, UK. E-mail:
                        <email>ian.white@mrc-bsu.cam.ac.uk</email></corresp>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <month>12</month>
        <year>2010</year>
      </pub-date>
      <!--Fake  ppub date generated  by PMC from publisher pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <month>12</month>
        <year>2010</year>
      </pub-date>
      <volume>7</volume>
      <issue>6</issue>
      <fpage>664</fpage>
      <lpage>676</lpage>
      <permissions>
        <copyright-statement>&#xA9; The Author(s), 2010. Reprints and permissions:
                    http://www.sagepub.co.uk/journalsPermissions.nav</copyright-statement>
        <copyright-year>2010</copyright-year>
        <copyright-holder content-type="sage">SAGE Publications</copyright-holder>
      </permissions>
      <abstract>
        <p><bold><italic>Background</italic></bold> Departures from randomized treatments
                    complicate the analysis of many randomized controlled trials. Intention-to-treat
                    analysis estimates the effect of <italic>being allocated to</italic> treatment.
                    It is now possible to estimate the effect of <italic>receiving</italic>
                    treatment without assuming comparability of groups defined by actual treatment.
                    However, the methodology is largely confined to trials where the only treatment
                    changes were switches to other trial treatments.</p>
        <p><bold><italic>Purpose</italic></bold> To propose a method for comparing the
                    effects of receiving trial treatments in an active-controlled clinical trial
                    where some participants received nontrial treatments and others received no
                    treatment at all, and to illustrate the method in the PENTA 5 trial in
                    HIV-infected children.</p>
        <p><bold><italic>Methods</italic></bold> We combine the instrumental variables
                    approach, which forms unbiased estimating equations based on the randomization
                    but does not fully identify the contrasts of trial treatment effects, with prior
                    information about the distribution of possible effects of nontrial treatments
                    and of one trial treatment; we do not need to use prior information about the
                    comparisons of trial treatments. Prior information in PENTA 5 was elicited from
                    the investigators.</p>
        <p><bold><italic>Results</italic></bold> In PENTA 5, the prior information suggested
                    that all treatments were beneficial, but there was uncertainty about the degree
                    of benefit. Allowing for this prior information changed point estimates and
                    increased standard errors compared with ignoring nontrial treatments.</p>
        <p><bold><italic>Limitations</italic></bold> The method depends on the correct
                    specification of the causal effect of treatment: in PENTA 5, this assumed a
                    linear effect of dose and no interactions between treatments. This specification
                    is hard to check from the data but can be explored in sensitivity analyses.
                    Prior information would be better derived from the literature whenever
                    possible.</p>
        <p><bold><italic>Conclusions</italic></bold> The use of partial prior information
                    gives a way to adjust for complex patterns of departures from randomized
                    treatments. It should be useful in all trials where nontrial treatments are used
                    and in active-controlled trials where trial treatments are not universally
                    used.</p>
      </abstract>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro" id="sec1-1740774510382439">
      <title>Introduction</title>
      <p>Many forms of departure from randomized treatment occur in clinical trials:
                nonreceipt of randomized treatment (sometimes termed noncompliance), receipt of the
                treatment allocated to a different trial arm (sometimes termed contamination), or
                receipt of a nontrial treatment, defined as a treatment not randomly allocated in
                the trial. Intention-to-treat (ITT) analysis is accepted as a valid way to explore
                the effect of <italic>allocating</italic> treatment [<xref ref-type="bibr" rid="bibr1-1740774510382439">1</xref>]. However, there has long been interest in
                estimating the causal effect of <italic>receiving</italic> treatment [<xref ref-type="bibr" rid="bibr2-1740774510382439">2</xref>]. Modern statistical
                methods are able to base such estimation on comparisons of randomized groups [<xref ref-type="bibr" rid="bibr3-1740774510382439">3</xref>], unlike popular methods
                such as per-protocol analysis which invalidly compare subgroups with different
                receipt of treatment [<xref ref-type="bibr" rid="bibr4-1740774510382439">4</xref>].</p>
      <p>Much statistical literature assumes that participants can only switch to receive the
                treatment allocated to a different trial arm, a situation with the convenient
                property that the ITT analysis also tests the null hypothesis of equivalence of the
                randomized treatments. This article considers the more difficult, but common, case
                where participants can receive nontrial treatments. In this case, the ITT analysis
                does not test the equivalence of the randomized treatments: for example, one
                treatment could appear better simply because participants receiving that treatment
                were more likely to change to an effective nontrial treatment.</p>
      <p>The difficulty introduced by participants receiving nontrial treatments is that the
                effects of these treatments must be included in a statistical model, but cannot
                easily be estimated from the trial data. Past work has addressed this problem by
                assuming that there are no unmeasured confounders [<xref ref-type="bibr" rid="bibr5-1740774510382439">5</xref>,<xref ref-type="bibr" rid="bibr6-1740774510382439">6</xref>] or by making strong distributional
                assumptions [<xref ref-type="bibr" rid="bibr7-1740774510382439">7</xref>,<xref ref-type="bibr" rid="bibr8-1740774510382439">8</xref>]. Our approach avoids such
                assumptions and instead uses information external to the trial to place informative
                prior distributions on the effects on nontrial treatments. To do this, we introduce
                a hybrid of Bayesian inference [<xref ref-type="bibr" rid="bibr9-1740774510382439">9</xref>,<xref ref-type="bibr" rid="bibr10-1740774510382439">10</xref>] and
                instrumental variables methods [<xref ref-type="bibr" rid="bibr11-1740774510382439">11</xref>].</p>
      <p>A particular application of our proposed methodology is to equivalence and
                noninferiority trials in which some participants receive no treatment, since receipt
                of no treatment introduces the same issues as receipt of nontrial treatments. ITT
                analysis is generally held to be anti-conservative for equivalence and
                noninferiority trials [<xref ref-type="bibr" rid="bibr12-1740774510382439">12</xref>]. Per-protocol analysis is commonly done [<xref ref-type="bibr" rid="bibr13-1740774510382439">13</xref>], but better methods are needed [<xref ref-type="bibr" rid="bibr14-1740774510382439">14</xref>].</p>
      <p>In this article, we first present the hybrid approach in general. We then show using
                a simple example how comparing the causal effects of trial treatments depend on the
                effects of the nontrial treatments, and we illustrate the hybrid approach. We next
                present an application to PENTA 5, a three-arm comparative trial in pediatric HIV
                patients in which some children received no treatment and others received nontrial
                treatments. We describe how we elicited and used expert priors, the results with the
                various prior distributions that were considered, and the implications. Finally, the
                discussion places this work in the wider context of the noncompliance
                literature.</p>
    </sec>
    <sec id="sec2-1740774510382439">
      <title>Proposed method</title>
      <sec id="sec3-1740774510382439">
        <title>Basic assumptions</title>
        <p>In Rubin's causal model [<xref ref-type="bibr" rid="bibr15-1740774510382439">15</xref>], participant <italic>i</italic> has
                    a set of counterfactual outcomes
                        <italic>Y</italic><sub><italic>i</italic></sub>(<inline-graphic xlink:href="10.1177_1740774510382439-img1.jpg"/>), where <inline-graphic xlink:href="10.1177_1740774510382439-img2.jpg"/> represents a potential set
                    of treatments, or drug dosages. For each participant only one of this set of
                    outcomes is observed,
                        <italic>Y</italic><sub><italic>i</italic></sub>(<italic>D</italic><sub><italic>i</italic></sub>).
                    Two assumptions are implicit in this notation. The Stable Unit Treatment Value
                    Assumption (SUTVA) [<xref ref-type="bibr" rid="bibr15-1740774510382439">15</xref>] states that the set of counterfactual outcomes for a particular
                    participant is a function of <italic>that</italic> participant's
                    potential treatments, and is not in any way influenced by <italic>other</italic>
                    participants' potential treatments. The <italic>exclusion
                        restriction</italic> assumption states that randomization has no
                        <italic>direct</italic> effect on the outcome, and may only have an indirect
                    effect through its effect on treatment actually received. Thus if a participant
                        <italic>would</italic> receive an identical treatment regardless of their
                    randomized treatment, then their counterfactual outcomes would be identical in
                    all such arms. All potential outcomes are assumed to be independent of
                    randomization.</p>
      </sec>
      <sec id="sec4-1740774510382439">
        <title>Model</title>
        <p>For the <italic>i</italic>-th participant, let
                            <italic>R</italic><sub><italic>i</italic></sub> be their randomized
                    group, taking values
                        1,&#x2009;2,&#x2009;&#x2026;&#x2009;,&#x2009;<italic>g</italic>; let
                            <bold><italic>D</italic></bold><sub><italic>i</italic></sub> be a
                        <italic>p</italic>-dimensional vector of their actual amount of the trial
                    and nontrial treatments (or dosages, for drug treatments); let
                        <italic>Y</italic><sub><italic>i</italic></sub> be their observed outcome;
                    and let <italic>Y</italic><sub><italic>i</italic></sub>(0) be their
                    counterfactual untreated outcome which would have been observed if no treatment
                    had been received.</p>
        <p>We define a causal model relating the observed outcome for the
                    <italic>i</italic>-th participant to the same participant's
                    counterfactual untreated outcome [<xref ref-type="bibr" rid="bibr16-1740774510382439">16</xref>]:<disp-formula id="eq1-1740774510382439"><label>(1)</label><graphic xlink:href="10.1177_1740774510382439-eq1"/></disp-formula>where
                        <bold>&#x3B1;</bold> is a <italic>p</italic>-dimensional set of causal
                    parameters for the trial and nontrial treatments. This model assumes that the
                    treatments have an additive, linear effect proportional to the dose taken. For
                    any individuals with
                        <bold><italic>D</italic></bold><sub><italic>i</italic></sub>&#x2009;=&#x2009;0,
                    consistency between <italic>Y</italic><sub><italic>i</italic></sub> and
                        <italic>Y</italic><sub><italic>i</italic></sub>(0) requires
                            &#x3F5;<sub><italic>i</italic></sub>&#x2009;=&#x2009;0. We
                    also assume<disp-formula id="eq2-1740774510382439"><label>(2)</label><graphic xlink:href="10.1177_1740774510382439-eq2"/></disp-formula>where
                            <bold><italic>X</italic></bold><sub><italic>i</italic></sub> is a set of
                    baseline covariates. Random variation is captured by the within-individual error
                            &#x3F5;<sub><italic>i</italic></sub> with
                            <bold>E</bold>[&#x3F5;<sub><italic>i</italic></sub>|<bold><italic>X</italic></bold><sub><italic>i</italic></sub>,
                        <italic>R</italic><sub><italic>i</italic></sub>]&#x2009;=&#x2009;0
                    and the between-individual error &#x3B4;<sub><italic>i</italic></sub> with
                        <bold>E</bold>[&#x3B4;<sub><italic>i</italic></sub>|<bold><italic>X</italic></bold><sub><italic>i</italic></sub>,
                        <italic>R</italic><sub><italic>i</italic></sub>]&#x2009;=&#x2009;0.</p>
        <p>The parameter <bold>&#x3B1;</bold> requires careful interpretation. Making the
                    stronger assumption
                            <bold>E</bold>[&#x3F5;<sub><italic>i</italic></sub>|<bold><italic>D</italic></bold><sub><italic>i</italic></sub>,
                            <bold><italic>X</italic></bold><sub><italic>i</italic></sub>,
                        <italic>R</italic><sub><italic>i</italic></sub>]&#x2009;=&#x2009;0
                    allows us to interpret <bold><italic>d</italic>&#x2032;&#x3B1;</bold> as the
                    average causal effect of a dose <bold><italic>d</italic></bold>
                    <italic>among those who receive dose <bold>d</bold></italic>. It cannot be
                    interpreted as the average causal effect of dose <bold><italic>d</italic></bold>
                    <italic>among all individuals</italic>, unless we also assume that treatment
                    assignment is independent of treatment benefit [<xref ref-type="bibr" rid="bibr17-1740774510382439">17</xref>].</p>
      </sec>
      <sec id="sec5-1740774510382439">
        <title>Ordinary least-squares estimation</title>
        <p>One way to estimate <bold>&#x3B1;</bold> is to regress
                            <italic>Y</italic><sub><italic>i</italic></sub> on
                            <bold><italic>D</italic></bold><sub><italic>i</italic></sub>.
                    Unfortunately, this is only valid if
                        <italic>Y</italic><sub><italic>i</italic></sub>(0) is uncorrelated with
                            <bold><italic>D</italic></bold><sub><italic>i</italic></sub>, which is
                    usually unrealistic: participants with a good prognosis usually show different
                    patterns of <italic>D</italic> to those with a poor prognosis. Sometimes,
                    confounding variables <italic>X</italic> can be measured and included in the
                    analysis in order to motivate a &#x2018;no unmeasured confounders&#x2019;
                    assumption that <italic>Y</italic><sub><italic>i</italic></sub>(0) is
                    uncorrelated with <bold><italic>D</italic></bold><sub><italic>i</italic></sub>
                    given <italic>X</italic>, but this is rarely plausible. We do not consider this
                    method further.</p>
      </sec>
      <sec id="sec6-1740774510382439">
        <title>Instrumental variables estimation</title>
        <p>A better approach to estimating the parameters uses the idea of instrumental
                    variables (IV). Combining Equations <xref ref-type="disp-formula" rid="eq1-1740774510382439">Equations (1)</xref> and <xref ref-type="disp-formula" rid="eq2-1740774510382439">(2)</xref> and taking the
                    expectation conditional on <bold><italic>X</italic></bold> and
                        <italic>R</italic> gives<disp-formula id="eq3-1740774510382439"><label>(3)</label><graphic xlink:href="10.1177_1740774510382439-eq3"/></disp-formula>We
                    estimate <bold>&#x3B1;</bold> in two stages. First, we fit a linear regression
                    for the <italic>d</italic>-th treatment dose,<disp-formula id="eq4-1740774510382439"><label>(4)</label><graphic xlink:href="10.1177_1740774510382439-eq4"/></disp-formula>for each
                        <italic>d</italic>&#x2009;=&#x2009;1 to <italic>p</italic>, where
                            <bold><italic>R</italic></bold><sub><italic>i</italic></sub> is a vector
                    of dummy variables for randomized group. We assemble the <italic>p</italic>
                    fitted values into a vector <inline-formula><mml:math id="ilm1-1740774510382439"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi mathvariant="bold-italic">D</mml:mi></mml:mrow><mml:mi>&#x2227;</mml:mi></mml:mover></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi mathvariant="bold-italic">D</mml:mi></mml:mrow><mml:mi>&#x2227;</mml:mi></mml:mover></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mi>i,</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula>. Then we estimate
                    &#x3B1; in the linear regression<disp-formula id="eq5-1740774510382439"><label>(5)</label><graphic xlink:href="10.1177_1740774510382439-eq5"/></disp-formula></p>
      </sec>
      <sec id="sec7-1740774510382439">
        <title>Identification</title>
        <p>Regression <xref ref-type="disp-formula" rid="eq5-1740774510382439">(5)</xref> is
                    only identified if the number of unknown treatment effects <italic>p</italic> is
                    less than the number of arms <italic>g</italic>. For example, in a two-arm trial
                    comparing two treatments, in which some individuals receive no treatment, <xref ref-type="disp-formula" rid="eq5-1740774510382439">Equation (5)</xref> does
                    not identify the two unknown treatment effects, since there is only one contrast
                    between trial arms. We will consider this example further below.</p>
        <p>There are various ways to deal with nonidentification. First, we could expand the
                    causal model to a <italic>full probability model</italic>, modeling the
                    association between <italic>Y</italic>(0) and
                            <bold><italic>D</italic></bold><sub><italic>i</italic></sub>, and
                    estimating the model using maximum likelihood [<xref ref-type="bibr" rid="bibr18-1740774510382439">18</xref>]. However, this approach can be
                    sensitive to model mis-specification [<xref ref-type="bibr" rid="bibr19-1740774510382439">19</xref>].</p>
        <p>Second, we could include interactions between
                            <bold><italic>X</italic></bold><sub><italic>i</italic></sub> and
                            <bold><italic>R</italic></bold><sub><italic>i</italic></sub> in model
                        <xref ref-type="disp-formula" rid="eq4-1740774510382439">(4)</xref>, as is
                    done in structural mean models [<xref ref-type="bibr" rid="bibr20-1740774510382439">20</xref>,<xref ref-type="bibr" rid="bibr21-1740774510382439">21</xref>]. Including such interactions
                    typically identifies the treatment effects <bold>&#x3B1;</bold>, but such
                    identification is highly dependent on the assumption that the causal effect does
                    not vary with <bold><italic>X</italic></bold> [<xref ref-type="bibr" rid="bibr16-1740774510382439">16</xref>]. In this article we do not include
                    such interactions, but they are explored separately [<xref ref-type="bibr" rid="bibr22-1740774510382439">22</xref>].</p>
        <p>Third, we could perform a sensitivity analysis in which we separate the model
                    parameters into two groups: the &#x2018;protocol effects&#x2019;
                        <bold>&#x3B1;</bold><sub><italic>p</italic></sub> which would have been
                    estimated if there had been perfect compliance, and the &#x2018;nonprotocol
                    effects&#x2019; <bold>&#x3B1;</bold><sub><italic>n</italic></sub> which would
                    have been irrelevant if there had been perfect compliance. In trials comparing
                    active treatments, the protocol effects would be contrasts of active treatments,
                    while the nonprotocol effects would be the effect of one trial treatment and the
                    effects of any nontrial treatments used (so that they are not uniquely defined:
                    see &#x2018;Obtaining prior information&#x2019;) later. The sensitivity
                    analysis would then estimate the protocol effects over a range of plausible
                    values of the nonprotocol effects.</p>
      </sec>
      <sec id="sec8-1740774510382439">
        <title>Hybrid estimation</title>
        <p>Building on the idea of sensitivity analysis, our proposal in this article is to
                    combine IV estimation with prior information about the nonprotocol effects in
                    order to identify the model. The next section will discuss how the prior
                    information may be obtained. To implement the method, we use a Bayesian
                    approach. We first fit the linear regression <xref ref-type="disp-formula" rid="eq4-1740774510382439">(4)</xref> and sample from the posterior
                    distribution of parameters <bold>&#x3B2;</bold>. For each sampled value, we
                    compute <inline-formula><mml:math id="ilm2-1740774510382439"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi mathvariant="bold-italic">D</mml:mi></mml:mrow><mml:mi>&#x2227;</mml:mi></mml:mover></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">X</mml:mi></mml:mrow><mml:mrow><mml:mi>i,</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula>. We then consider the
                    linear regression <xref ref-type="disp-formula" rid="eq5-1740774510382439">(5)</xref> with prior <italic>p</italic>(<bold>&#x3B1;</bold>) and sample
                    from the posterior distribution of <bold>&#x3B1;</bold> and &#x3B3;.</p>
        <p>This procedure is conveniently implemented in WinBUGS [<xref ref-type="bibr" rid="bibr10-1740774510382439">10</xref>]. It could be considered a Bayesian
                    procedure using a partial likelihood that does not consider the relationship
                    between <italic>D</italic>, &#x3B4;, and &#x3F5;. Alternatively, it could be
                    considered a probabilistic sensitivity analysis for IV estimation where any
                    unidentified parameters may be imputed following an informative prior
                    distribution [<xref ref-type="bibr" rid="bibr23-1740774510382439">23</xref>].
                    Its advantages are enabling the use of prior identifying information and
                    allowing for uncertainty in the parameters of
                            <italic>E</italic>[<bold><italic>D</italic></bold>|<bold><italic>X</italic></bold>,
                        <italic>R</italic>].</p>
      </sec>
      <sec id="sec9-1740774510382439">
        <title>Obtaining prior information</title>
        <p>The nonprotocol effects are commonly effects of widely used treatments, so
                    results of relevant randomized trials or meta-analyses of such trials would
                    ideally be available as prior information. In some cases, however, trials or
                    meta-analyses are inadequate, and it is preferable to elicit prior information
                    from experts [<xref ref-type="bibr" rid="bibr24-1740774510382439">24</xref>].</p>
        <p>In practice, one may elicit a prior distribution for all of
                        <bold>&#x3B1;</bold> rather than just for the nonprotocol parameters; this
                    was done in the case study below. A fully Bayesian analysis would use this full
                    prior <italic>p</italic>(<bold>&#x3B1;</bold>). However, we argue against
                    using prior beliefs about the protocol effects, because we would not usually use
                    this information in a clinical trial without noncompliance, and because it is
                    not needed in order to adjust for noncompliance. We prefer to use prior
                    information only where it is needed to achieve identifiability.</p>
        <p>There is usually more than one way to achieve identifiability, because there is
                    more than one reasonable way to define the nonprotocol parameters. We propose
                    using the full expert prior to define the nonprotocol parameters
                        <bold>&#x3B1;</bold><sub><italic>n</italic></sub> as a linear combination
                    of parameters in <bold>&#x3B1;</bold> that are uncorrelated with
                        <bold>&#x3B1;</bold><sub><italic>p</italic></sub> in the prior
                    distribution. We then modify the full prior distribution by giving a large value
                    to the prior variance of the protocol effects: that is, we use the expert prior
                    for <bold>&#x3B1;</bold><sub><italic>n</italic></sub> and a vague prior for
                        <bold>&#x3B1;</bold><sub><italic>p</italic></sub>. This method has the
                    desirable property that the same prior is obtained, however,
                        <bold>&#x3B1;</bold><sub><italic>p</italic></sub> is defined. In the case
                    of complete compliance, or just switching between trial treatments, the prior
                    will become redundant, as would be desired. Details of how to compute such a set
                    of constrasts are given in <xref ref-type="app" rid="app4-1740774510382439">appendix D</xref>.</p>
      </sec>
    </sec>
    <sec id="sec10-1740774510382439">
      <title>Simple example</title>
      <p>We now consider a two-arm trial comparing experimental with standard treatment, where
                participants may receive either treatment, both treatments or neither treatment, but
                receipt of any one treatment is all-or-nothing. As before,
                        <italic>R</italic><sub><italic>i</italic></sub> indicates whether
                participant <italic>i</italic> was randomized to treatment 1 or 2,
                    <italic>Y</italic><sub><italic>i</italic></sub> is their actual (quantitative)
                outcome, and <italic>Y</italic><sub><italic>i</italic></sub>(0) is their
                counterfactual untreated outcome. In this setting, treatment for participant
                    <italic>i</italic> is summarized by two binary variables
                        <italic>D</italic><sub><italic>di</italic></sub> indicating whether or not
                they took treatment <italic>d</italic>&#x2009;=&#x2009;1, 2. The causal
                model <xref ref-type="disp-formula" rid="eq1-1740774510382439">(1)</xref> then
                    becomes<disp-formula id="eq6-1740774510382439"><label>(6)</label><graphic xlink:href="10.1177_1740774510382439-eq6"/></disp-formula>where, as
                before, &#x3F5;<sub><italic>i</italic></sub> has mean zero, is uncorrelated with
                randomized group and actual treatment and equals 0 if
                        <italic>D</italic><sub>1<italic>i</italic></sub>&#x2009;=&#x2009;<italic>D</italic><sub>2<italic>i</italic></sub>&#x2009;=&#x2009;0.</p>
      <p>The target of inference is the &#x2018;protocol effect&#x2019;
                        &#x3B1;<sub><italic>p</italic></sub>&#x2009;=&#x2009;&#x3B1;<sub>1</sub>&#x2009;&#x2212;&#x2009;&#x3B1;<sub>2</sub>.
                Strictly, this is the difference between the average effect of treatment 1 in those
                who receive treatment 1 and the average effect of treatment 2 in those who receive
                treatment 2. It seems reasonable to believe that the average effect of treatment 1
                in those who received it is unaffected by whether they <italic>would have
                    received</italic> treatment 2 if allocated to it. Therefore the protocol effect
                may be interpreted as the ITT difference in perfect compliers [<xref ref-type="bibr" rid="bibr22-1740774510382439">22</xref>].</p>
      <p>We initially consider the case where treatment 1 is new and treatment 2 is a standard
                treatment, so we are likely to have more prior knowledge about &#x3B1;<sub>2</sub>
                than about &#x3B1;<sub>1</sub>, and we define the nonprotocol effect as
                        &#x3B1;<sub><italic>n</italic></sub>&#x2009;=&#x2009;&#x3B1;<sub>2</sub>.</p>
      <sec id="sec11-1740774510382439">
        <title>Estimation by instrumental variables</title>
        <p>Randomization ensures that the distributions of the error term
                            &#x3F5;<sub><italic>i</italic></sub> and the untreated outcome
                        <italic>Y</italic><sub><italic>i</italic></sub>(0) are identical in both
                    arms, suggesting the unbiased estimating equation<disp-formula id="eq7-1740774510382439"><label>(7)</label><graphic xlink:href="10.1177_1740774510382439-eq7"/></disp-formula>where
                        <italic>n</italic><sub>1</sub> and <italic>n</italic><sub>2</sub> are the
                    sample sizes in the two arms. We write this as<disp-formula id="eq8-1740774510382439"><label>(8)</label><graphic xlink:href="10.1177_1740774510382439-eq8"/></disp-formula>where <inline-formula><mml:math id="ilm3-1740774510382439"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mo>&#xAF;</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>dr</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>
                    and <inline-formula><mml:math id="ilm4-1740774510382439"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>Y</mml:mi></mml:mrow><mml:mo>&#xAF;</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>r</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>
                    are the mean of <italic>D</italic><sub><italic>di</italic></sub> and
                        <italic>Y</italic><sub><italic>i</italic></sub> in arm <italic>r</italic>,
                    and hence<disp-formula id="eq9-1740774510382439"><label>(9)</label><graphic xlink:href="10.1177_1740774510382439-eq9"/></disp-formula>
                    <xref ref-type="disp-formula" rid="eq9-1740774510382439"> Equation (9)</xref>
                    shows that we cannot in general estimate the protocol effect
                        &#x3B1;<sub>1</sub>&#x2009;&#x2212;&#x2009;&#x3B1;<sub>2</sub>
                    without knowing the nonprotocol effect &#x3B1;<sub>2</sub>. The only exception
                    is if <inline-formula><mml:math id="ilm5-1740774510382439"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mo>&#xAF;</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>22</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mo>&#xAF;</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>12</mml:mn></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mo>&#xAF;</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>11</mml:mn></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mo>&#xAF;</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>21</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math></inline-formula>,
                    which occurs in the special case when the participants can only switch
                    treatments. In this case the estimate of
                        &#x3B1;<sub>1</sub>&#x2009;&#x2212;&#x2009;&#x3B1;<sub>2</sub> is
                    well defined and is the standard IV estimate <inline-formula><mml:math id="ilm6-1740774510382439"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>Y</mml:mi></mml:mrow><mml:mo>&#xAF;</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>Y</mml:mi></mml:mrow><mml:mo>&#xAF;</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>/</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mo>&#xAF;</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>11</mml:mn></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mo>&#xAF;</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>12</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula>. In the case of perfect
                    compliance, <inline-formula><mml:math id="ilm7-1740774510382439"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mo>&#xAF;</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>11</mml:mn></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mo>&#xAF;</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>12</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula>,
                    so the estimate equals the standard ITT estimate <inline-formula><mml:math id="ilm8-1740774510382439"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>Y</mml:mi></mml:mrow><mml:mo>&#xAF;</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>Y</mml:mi></mml:mrow><mml:mo>&#xAF;</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>.</p>
        <p>Now suppose we have external knowledge about &#x3B1;<sub>2</sub>, the causal
                    effect of the standard treatment. Expressing this knowledge as a probability
                    distribution with mean <italic>m</italic><sub>&#x3B1;<sub>2</sub></sub> and
                    variance <inline-formula><mml:math id="ilm9-1740774510382439"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>&#x3B1;</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula>,
                    our best estimate is<disp-formula id="eq10-1740774510382439"><label>(10)</label><graphic xlink:href="10.1177_1740774510382439-eq10"/></disp-formula>with
                    approximate variance<disp-formula id="eq11-1740774510382439"><label>(11)</label><graphic xlink:href="10.1177_1740774510382439-eq11"/></disp-formula>where
                    &#x3C3; is the standard deviation of <italic>Y</italic> in each arm. The two
                    terms in the numerator of <xref ref-type="disp-formula" rid="eq11-1740774510382439">(11)</xref> allow for uncertainty in the data
                    about <inline-formula><mml:math id="ilm10-1740774510382439"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>Y</mml:mi></mml:mrow><mml:mo>&#xAF;</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>Y</mml:mi></mml:mrow><mml:mo>&#xAF;</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>
                    and prior uncertainty about &#x3B1;<sub>2</sub>, respectively. (We ignore for
                    illustrative purposes the uncertainty in the <inline-formula><mml:math id="ilm11-1740774510382439"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mo>&#xAF;</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>dr</mml:mi></mml:mrow></mml:msub><mml:mi>&#x2003;</mml:mi></mml:mrow></mml:math></inline-formula>,
                    which is typically much less than the uncertainty in the <inline-formula><mml:math id="ilm12-1740774510382439"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>Y</mml:mi></mml:mrow><mml:mo>&#xAF;</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>r</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>.)
                    The role of the external knowledge is typically limited, because the term <inline-formula><mml:math id="ilm13-1740774510382439"><mml:mrow><mml:mrow><mml:mo>{</mml:mo><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mo>&#xAF;</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>22</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mo>&#xAF;</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>12</mml:mn></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mo>&#xAF;</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>11</mml:mn></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mo>&#xAF;</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>21</mml:mn></mml:mrow></mml:msub><mml:mo>}</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula>
                    is typically small: it represents the difference in treatment in arm 2 compared
                    with arm 1, summed over treatments.</p>
        <p>We have so far assumed that treatment 1 is new. If instead the trial is a
                    head-to-head comparison of two existing treatments, one might use prior
                    knowledge about <inline-formula><mml:math id="ilm14-1740774510382439"><mml:mrow><mml:mover><mml:mrow><mml:mi>&#x3B1;</mml:mi></mml:mrow><mml:mo>&#xAF;</mml:mo></mml:mover><mml:mo>=</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi>&#x3B1;</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>&#x3B1;</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>/</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:math></inline-formula>.
                    This suggests replacing <xref ref-type="disp-formula" rid="eq9-1740774510382439"> Equation (9)</xref> with<disp-formula id="eq12-1740774510382439"><label>(12)</label><graphic xlink:href="10.1177_1740774510382439-eq12"/></disp-formula>Given a
                    full expert prior <italic>p</italic>(&#x3B1;<sub>1</sub>,
                        &#x3B1;<sub>2</sub>), we could also define
                            &#x3B1;<sub><italic>n</italic></sub> to be uncorrelated with
                            &#x3B1;<sub><italic>p</italic></sub> in the prior, as described
                    above.</p>
      </sec>
      <sec id="sec12-1740774510382439">
        <title>Numerical example</title>
        <p>We illustrate these ideas using a fictitious data set with imperfect compliance
                        (<xref ref-type="table" rid="table1-1740774510382439">Table 1</xref>). If
                        &#x3B1;<sub>2</sub> were known then we could use <xref ref-type="disp-formula" rid="eq9-1740774510382439"> Equation (9)</xref> to
                    show <inline-formula><mml:math id="ilm15-1740774510382439"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>&#x3B1;</mml:mi></mml:mrow><mml:mi>&#x2227;</mml:mi></mml:mover></mml:mrow><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mn>0</mml:mn><mml:mo>.</mml:mo><mml:mn>2</mml:mn><mml:msub><mml:mrow><mml:mi>&#x3B1;</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>.</mml:mo><mml:mn>8</mml:mn></mml:mrow></mml:mfrac></mml:mrow></mml:math></inline-formula>.
                    Instead, we use various priors for
                        &#x3B1;<sub><italic>n</italic></sub>&#x2009;=&#x2009;&#x3B1;<sub>2</sub>,
                    using <xref ref-type="disp-formula" rid="eq10-1740774510382439"> Equations
                        (10)</xref> and <xref ref-type="disp-formula" rid="eq11-1740774510382439">(11)</xref>. The first four rows of <xref ref-type="table" rid="table2-1740774510382439">Table 2</xref> have priors centered at
                        &#x3B1;<sub>2</sub>&#x2009;=&#x2009;0. They all have point
                    estimate <inline-formula><mml:math id="ilm16-1740774510382439"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>&#x3B1;</mml:mi></mml:mrow><mml:mi>&#x2227;</mml:mi></mml:mover></mml:mrow><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>&#x2009;=&#x2009;1.25,
                    but the standard error of <inline-formula><mml:math id="ilm17-1740774510382439"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>&#x3B1;</mml:mi></mml:mrow><mml:mi>&#x2227;</mml:mi></mml:mover></mml:mrow><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>
                    increases with uncertainty about &#x3B1;<sub>2</sub> (although this standard
                    error is much smaller than the prior uncertainty about &#x3B1;<sub>2</sub>).
                    The next four rows of <xref ref-type="table" rid="table2-1740774510382439">Table
                        2</xref> change the prior mean from 0 to 1, which reduces the posterior mean
                    from 1.25 to 1 &#x2013; a smaller change, but one that could still be
                    practically important. <table-wrap id="table1-1740774510382439" position="float"><label>Table
                            1</label><caption><p>Data for simple example</p></caption><table frame="hsides" rules="groups"><thead align="left"><tr><th rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Arm 1</th><th align="center" rowspan="1" colspan="1">Arm 2</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Mean outcome, <inline-formula><mml:math id="ilm18-1740774510382439"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>Y</mml:mi></mml:mrow><mml:mo>&#xAF;</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>r</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula></td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">Outcome SD, &#x3C3;</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">Sample size, <italic>n</italic></td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">100</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean use of treatment 1, <inline-formula><mml:math id="ilm19-1740774510382439"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mo>&#xAF;</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula></td><td align="center" rowspan="1" colspan="1">0.8</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean use of treatment 2, <inline-formula><mml:math id="ilm20-1740774510382439"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mo>&#xAF;</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula></td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0.6</td></tr></tbody></table></table-wrap>
                    <table-wrap id="table2-1740774510382439" position="float"><label>Table
                                2</label><caption><p>Results for simple example</p></caption><table frame="hsides" rules="groups"><thead align="left"><tr><th align="left" rowspan="2" colspan="1">Prior
                                            <italic>p</italic>(&#x3B1;<sub>2</sub>)</th><th colspan="2" align="center" rowspan="1"><hr/>Posterior for
                                                &#x3B1;<sub><italic>p</italic></sub>&#x2009;=&#x2009;&#x3B1;<sub>1</sub>&#x2009;&#x2212;&#x2009;&#x3B1;<sub>2</sub></th></tr><tr><th align="center" rowspan="1" colspan="1">Mean</th><th align="center" rowspan="1" colspan="1">Standard error</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><italic>N</italic>(0, 0<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">1.25</td><td align="center" rowspan="1" colspan="1">0.18</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>N</italic>(0, 0.5<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">1.25</td><td align="center" rowspan="1" colspan="1">0.22</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>N</italic>(0, 1<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">1.25</td><td align="center" rowspan="1" colspan="1">0.31</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>N</italic>(0, 2<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">1.25</td><td align="center" rowspan="1" colspan="1">0.53</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>N</italic>(1, 0<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">1.00</td><td align="center" rowspan="1" colspan="1">0.18</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>N</italic>(1, 0.5<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">1.00</td><td align="center" rowspan="1" colspan="1">0.22</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>N</italic>(1, 1<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">1.00</td><td align="center" rowspan="1" colspan="1">0.31</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>N</italic>(1, 2<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">1.00</td><td align="center" rowspan="1" colspan="1">0.53</td></tr></tbody></table></table-wrap></p>
      </sec>
    </sec>
    <sec id="sec13-1740774510382439">
      <title>Example: PENTA 5 trial</title>
      <sec id="sec14-1740774510382439">
        <title>Trial design</title>
        <p>The PENTA 5 trial [<xref ref-type="bibr" rid="bibr25-1740774510382439">25</xref>]
                    compared the effectiveness of three combination treatments for pediatric HIV-1
                    infection: lamivudine (3TC) + abacavir (ABC), zidovudine (ZDV) +
                    3TC, and ZDV + ABC. Of the 128 children randomized, 55 who were
                    initially symptom-free were additionally randomized to receive nelfinavir, a
                    protease inhibitor (PI), or placebo in an incomplete factorial design:
                    symptomatic children all received PI. In this analysis we include all 128
                    children but consider PI as a nontrial drug, ignoring the fact that it was
                    partly randomized.</p>
        <p>The children returned to the clinic at 4-week intervals up to 24 weeks and at
                    12-week intervals thereafter up to 224 weeks. The primary endpoint was the log
                    concentration of HIV RNA in plasma at 24 and 48 weeks. Here we focus on the
                    24-week outcome, defined as the outcome observed closest to 24 weeks within the
                    22&#x2013;30 week window. Baseline covariates included sex, ethnic origin, age,
                    CDC disease stage, CD4 cell count, and height-for-age Z-scores.</p>
      </sec>
      <sec id="sec15-1740774510382439">
        <title>Observed treatment</title>
        <p>The trial drugs ZDV, 3TC and ABC, and the nontrial PI were taken at many
                    different doses. <xref ref-type="table" rid="table3-1740774510382439">Table
                        3</xref> shows a &#x2018;recommended dose&#x2019; for each drug (the
                    protocol dose for the trial drugs and current best practice for the nontrial
                    drug), dependent on a child's weight or estimated body surface area. For
                    each drug, we defined the &#x2018;dose fraction&#x2019; for each child at each
                    clinic visit as the fraction of the &#x2018;recommended dose&#x2019; taken,
                    except that doses above the maximum adult dose had a dose fraction of 1 [<xref ref-type="bibr" rid="bibr16-1740774510382439">16</xref>]. The
                    &#x2018;standardized dose&#x2019; was defined as the dose fraction if a drug
                    had been taken without interruption; after interruption, the effect of the drug
                    may be diminished by possible acquisition of viral resistance, and the dose
                    fraction was multiplied by the &#x2018;re-start factor&#x2019; given in <xref ref-type="table" rid="table3-1740774510382439">Table 3</xref>. <table-wrap id="table3-1740774510382439" position="float"><label>Table 3</label><caption><p>PENTA 5
                                trial: recommended and maximum drug doses and re-start
                            factors</p></caption><table frame="hsides" rules="groups"><thead align="left"><tr><th align="left" rowspan="1" colspan="1">Type</th><th align="left" rowspan="1" colspan="1">Drug</th><th align="right" rowspan="1" colspan="1">Recommended dose</th><th align="right" rowspan="1" colspan="1">Maximum</th><th align="right" rowspan="1" colspan="1">Re-start</th></tr><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th align="right" rowspan="1" colspan="1">(mg)</th><th align="right" rowspan="1" colspan="1">(mg)</th><th align="right" rowspan="1" colspan="1">factor (%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Trial</td><td align="left" rowspan="1" colspan="1">ZDV</td><td align="right" rowspan="1" colspan="1">360 /m<sup>2</sup>/day</td><td align="right" rowspan="1" colspan="1">600</td><td align="right" rowspan="1" colspan="1">75</td></tr><tr><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">3TC</td><td align="right" rowspan="1" colspan="1">8 /kg/day</td><td align="right" rowspan="1" colspan="1">300</td><td align="right" rowspan="1" colspan="1">50</td></tr><tr><td rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ABC</td><td align="right" rowspan="1" colspan="1">16 /kg/day</td><td align="right" rowspan="1" colspan="1">600</td><td align="right" rowspan="1" colspan="1">50</td></tr><tr><td align="left" rowspan="1" colspan="1">Nontrial</td><td align="left" rowspan="1" colspan="1">PI</td><td align="right" rowspan="1" colspan="1">90 /kg/day</td><td align="right" rowspan="1" colspan="1">2500</td><td align="right" rowspan="1" colspan="1">75</td></tr></tbody></table></table-wrap></p>
        <p><italic>D</italic><sub>1<italic>i</italic></sub>,
                            <italic>D</italic><sub>2<italic>i</italic></sub>,
                            <italic>D</italic><sub>3<italic>i</italic></sub>, and
                            <italic>D</italic><sub>4<italic>i</italic></sub> were defined as the
                    standardized doses for ZDV, 3TC, ABC, and PI, respectively for child
                        <italic>i</italic> at 24 weeks. A box and whisker plot summarizing the
                    standardized doses, by randomized arm, is given in <xref ref-type="fig" rid="fig1-1740774510382439">Figure 1</xref>. <fig id="fig1-1740774510382439" position="float"><label>Figure 1</label><caption><p>PENTA 5 trial:
                                standardized drug dosages at 24 weeks</p></caption><graphic xlink:href="10.1177_1740774510382439-fig1"/></fig></p>
        <p>The focus of the trial is to estimate differences between 3TC &amp; ABC, ZDV
                    &amp; 3TC, and ZDV &amp; ABC [<xref ref-type="bibr" rid="bibr25-1740774510382439">25</xref>]. Assuming the drugs have an
                    additive effect, the contrasts of interest are then represented by
                        &#x3B1;<sub>2</sub>&#x2009;&#x2212;&#x2009;&#x3B1;<sub>1</sub> (3TC
                    &amp; ABC vs. ZDV &amp; ABC) and
                        &#x3B1;<sub>2</sub>&#x2009;&#x2212;&#x2009;&#x3B1;<sub>3</sub> (ZDV
                    &amp; 3TC vs. ZDV &amp; ABC). Thus the protocol effects are
                        <bold>&#x3B1;</bold><sub><italic>p</italic></sub>&#x2009;=&#x2009;(&#x3B1;<sub>2</sub>&#x2009;&#x2212;&#x2009;&#x3B1;<sub>1</sub>,
                        &#x3B1;<sub>2</sub>&#x2009;&#x2212;&#x2009;&#x3B1;<sub>3</sub>). We
                    consider how to assess sensitivity to the modeling assumptions in the
                    discussion. The nonprotocol effects are taken as
                            <bold>&#x3B1;</bold><sub><italic>n</italic></sub>&#x2009;=&#x2009;(&#x3B1;<sub>1</sub>&#x2009;+&#x2009;&#x3B1;<sub>3</sub>,
                        &#x3B1;<sub>4</sub>), representing the causal effect of ZDV &amp; ABC
                    versus no drugs and the causal effect of the nontrial PI drugs. We emphasize
                    that <bold>&#x3B1;</bold><sub><italic>p</italic></sub> is of primary clinical
                    interest; <bold>&#x3B1;</bold><sub><italic>n</italic></sub> is only important
                    because it is needed in order to estimate the protocol parameters.</p>
      </sec>
      <sec id="sec16-1740774510382439">
        <title>Expert prior</title>
        <p>To obtain expert opinion on drug effects, five clinicians active in the field of
                    HIV medicine and HIV clinical trials were sent a questionnaire describing 22
                    hypothetical randomized controlled trials (<xref ref-type="app" rid="app1-1740774510382439">Appendices A</xref> and <xref ref-type="app" rid="app2-1740774510382439">B</xref>). The trials compared the two- and
                    three-drug combinations of all trial and nontrial drugs actually used in PENTA
                    5, although several of these (the classes NRTI and nNRTI in the appendices) were
                    not in use at 24 weeks. For each trial, the questionnaire elicited the median,
                    75th and 87.5th quantile of the expert's prior distribution for the true
                    difference in log HIV RNA between the trial arms. The elicited data were
                    converted into a pooled multivariate Normal prior distribution with the
                    parameters given in <xref ref-type="table" rid="table4-1740774510382439">Table
                        4</xref>. <table-wrap id="table4-1740774510382439" position="float"><label>Table
                                4</label><caption><p>PENTA 5 trial: means, standard deviations and
                                correlation matrix of the expert prior distribution for the four
                                treatment effects</p></caption><table frame="hsides" rules="groups"><thead align="left"><tr><th rowspan="1" colspan="1"/><th align="right" rowspan="1" colspan="1"><hr/>ZDV (&#x3B1;<sub>1</sub>)</th><th align="right" rowspan="1" colspan="1"><hr/>3TC (&#x3B1;<sub>2</sub>)</th><th align="right" rowspan="1" colspan="1"><hr/>ABC (&#x3B1;<sub>3</sub>)</th><th align="right" rowspan="1" colspan="1"><hr/>PI (&#x3B1;<sub>4</sub>)</th></tr><tr><th rowspan="1" colspan="1">Mean</th><th align="right" rowspan="1" colspan="1">&#x2212;0.408</th><th align="right" rowspan="1" colspan="1">&#x2212;0.576</th><th align="right" rowspan="1" colspan="1">&#x2212;0.457</th><th align="right" rowspan="1" colspan="1">&#x2212;1.032</th></tr><tr><th rowspan="1" colspan="1">SD</th><th align="right" rowspan="1" colspan="1">0.418</th><th align="right" rowspan="1" colspan="1">0.478</th><th align="right" rowspan="1" colspan="1">0.443</th><th align="right" rowspan="1" colspan="1">0.525</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Correlation</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x2003;ZDV</td><td align="right" rowspan="1" colspan="1">1</td><td align="right" rowspan="1" colspan="1">0.41</td><td align="right" rowspan="1" colspan="1">0.32</td><td align="right" rowspan="1" colspan="1">0.45</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x2003;3TC</td><td rowspan="1" colspan="1"/><td align="right" rowspan="1" colspan="1">1</td><td align="right" rowspan="1" colspan="1">0.38</td><td align="right" rowspan="1" colspan="1">0.42</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x2003;ABC</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="right" rowspan="1" colspan="1">1</td><td align="right" rowspan="1" colspan="1">0.30</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x2003;PI</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="right" rowspan="1" colspan="1">1</td></tr></tbody></table></table-wrap></p>
      </sec>
      <sec id="sec17-1740774510382439">
        <title>Analysis model</title>
        <p>We modeled the dose of the <italic>d</italic>-th drug for child
                        <italic>i</italic> at 24 weeks using<disp-formula id="eq13-1740774510382439"><label>(13)</label><graphic xlink:href="10.1177_1740774510382439-eq13"/></disp-formula>where
                        <italic>R</italic><sub><italic>i</italic>1</sub> and
                            <italic>R</italic><sub><italic>i</italic>2</sub> are indicator variables
                    for the 3TC &amp; ABC and ZDV &amp; 3TC arms, and
                            <italic>Y</italic><sub><italic>i</italic>0</sub> is the baseline level
                    of log HIV RNA. The choice of covariates was based on statistical
                    significance.</p>
        <p>Our model for the primary outcome was<disp-formula id="eq14-1740774510382439"><label>(14)</label><graphic xlink:href="10.1177_1740774510382439-eq14"/></disp-formula></p>
        <p>The error terms, &#x3F5;<sub><italic>Ddi</italic></sub> and
                            &#x3F5;<sub><italic>Yi</italic></sub> were assumed to be independent,
                    normally distributed, with zero mean and variance <inline-formula><mml:math id="ilm21-1740774510382439"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>&#x3C3;</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula>
                    and <inline-formula><mml:math id="ilm22-1740774510382439"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>&#x3C3;</mml:mi></mml:mrow><mml:mrow><mml:mi>Y</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula>,
                    respectively.</p>
        <p>As described more fully in [<xref ref-type="bibr" rid="bibr16-1740774510382439">16</xref>], some outcome values were only reported as being below a cutoff.
                    The MCMC simulation approach easily copes with such censored data by imputing
                    the censored values under the assumption that the underlying distribution is
                    Normal. WinBUGS code is given in <xref ref-type="app" rid="app3-1740774510382439">Appendix C</xref>.</p>
        <p>For comparative purposes, we fitted an intention-to-treat (ITT) model which made
                    no use of the observed doses. The model fitted was similar to <xref ref-type="disp-formula" rid="eq14-1740774510382439"> Equation (14)</xref>
                    but with the four <inline-formula><mml:math id="ilm23-1740774510382439"><mml:mrow><mml:msub><mml:mrow><mml:mover><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mi>&#x2227;</mml:mi></mml:mover></mml:mrow><mml:mrow><mml:mi>dij</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>
                    terms replaced with two indicator variables for the 3TC &amp; ABC and ZDV
                    &amp; 3TC arms of the trial; the baseline log HIV RNA count term was
                    retained. A classical Tobit regression analysis was used to account for the
                    censored observations, replicating the approach used in [<xref ref-type="bibr" rid="bibr25-1740774510382439">25</xref>].</p>
      </sec>
      <sec id="sec18-1740774510382439" sec-type="results">
        <title>Results</title>
        <p>We considered five different choices of priors, the last three of which were
                    described above under &#x2018;Obtaining prior information&#x2019;: <list list-type="order"><list-item><p>An uninformative prior, <italic>N</italic>(0, 2<sup>2</sup>),
                                on the two nonprotocol effects. The value of 2 was chosen as a very
                                large value from the clinical context;</p></list-item><list-item><p>A &#x2018;na&#xEF;ve&#x2019; prior that assumes the value
                                of the nonprotocol parameters is zero;</p></list-item><list-item><p>Partial expert (method 1): the experts' full prior
                                distribution, with the marginal variance on the two protocol effects
                                changed to a large value, 1000, and with the prior for the two
                                nonprotocol effects unchanged;</p></list-item><list-item><p>Partial expert (method 2): as method 1, but with the two
                                nonprotocol parameters redefined to be independent of the protocol
                                parameters in the prior;</p></list-item><list-item><p>The experts' full prior distribution on both protocol
                                and nonprotocol parameters.</p></list-item></list></p>
        <p>Apart from these different specifications of the informative prior, broadly
                    noninformative priors were used for the remaining parameters: the coefficients
                    in the <italic>D</italic> models were <italic>N</italic>(0, 100); precisions for
                    all the error terms were &#x393;(0.01, 0.01);
                            <bold>&#x3B1;</bold><sub><italic>p</italic></sub> (except in the model
                    using the full prior) and &#x3B3; were <italic>N</italic>(0, 1000).</p>
        <p>The resulting confidence intervals for the two protocol parameters are shown in
                        <xref ref-type="fig" rid="fig2-1740774510382439">Figure 2</xref>. With the
                    uninformative prior, the data are fairly uninformative on the causal effect of
                    the trial drugs. The na&#xEF;ve prior gives much more certain results, but
                    makes the implausible assumption that nontrial treatments have no effect. The
                    two partial expert prior methods agree to a reasonable extent in both location
                    and width; we prefer method 2, since it is invariant to re-parameterization and
                    has a clear theoretical interpretation. The full expert prior gives results that
                    are similar to the partial expert prior but closer to the null, reflecting the
                    experts' prior beliefs being centered near the null. Recall that these
                    parameters require careful interpretation. The ITT analysis, also shown in <xref ref-type="fig" rid="fig2-1740774510382439">Figure 2</xref>, estimates the
                    treatment effect of 3TC &amp; ABC to be closer to the null than all the
                    other models, with a similar size confidence interval to the expert prior
                    analysis; the ITT treatment effect of ZDV &amp; 3TC is roughly comparable to
                    the two expert prior analysis. <fig id="fig2-1740774510382439" position="float"><label>Figure 2</label><caption><p>PENTA 5 trial: estimated parameters
                                under intention-to-treat (ITT) analysis and under causal analysis
                                with different priors</p></caption><graphic xlink:href="10.1177_1740774510382439-fig2"/></fig></p>
        <p>The qualitative conclusion is that 3TC &amp; ABC is the superior drug
                    combination, but the degree of its superiority depends on our opinion of the
                    effect of the other drugs.</p>
      </sec>
    </sec>
    <sec sec-type="discussion" id="sec19-1740774510382439">
      <title>Discussion</title>
      <p>We have proposed a way to estimate causal differences between treatments in a
                randomized trial with a complex pattern of nonreceipt of randomized treatments and
                receipt of nontrial treatments. Here we compare our approach with some alternative
                methods that have been proposed.</p>
      <p>The largest body of literature concerns causal analyses when the only treatment
                change is switching between the trial treatments. The intuitive presentation of
                Sommer and Zeger [<xref ref-type="bibr" rid="bibr26-1740774510382439">26</xref>] has
                been formalized by Angrist <italic>et al</italic>. [<xref ref-type="bibr" rid="bibr27-1740774510382439">27</xref>] and by the notion of principal strata
                    [<xref ref-type="bibr" rid="bibr28-1740774510382439">28</xref>], and widely
                extended [<xref ref-type="bibr" rid="bibr18-1740774510382439">18</xref>,<xref ref-type="bibr" rid="bibr29-1740774510382439">29</xref>&#x2013;<xref ref-type="bibr" rid="bibr31-1740774510382439">31</xref>]. These techniques
                estimate a single treatment contrast from a single randomization and do not extend
                to cases where some participants take nontrial treatments, or to comparative trials
                where some participants take no treatments, because in these settings it is
                necessary to estimate more parameters without having more randomizations.</p>
      <p>Some attempts have been made to handle nontrial treatments. Robins and Greenland
                considered a trial of low versus high dose of AZT in AIDS patients where the ITT
                analysis unexpectedly found that the low dose improved survival [<xref ref-type="bibr" rid="bibr5-1740774510382439">5</xref>], possibly due to
                imbalance in the receipt of a nontrial treatment (prophylaxis against
                    <italic>Pneumocystis carinii</italic> pneumonia). The authors estimated a
                structural nested failure time model involving the causal effects of the two
                treatments in two ways. First, they used two different weighted log-rank tests:
                since there were more parameters than randomized arms, this method gave very
                imprecise inferences, and depended strongly on distributional assumptions. Second,
                they estimated the effect of the nontrial treatment under the assumption that
                conditioning on recorded clinical variables was sufficient to make the decision to
                switch treatments independent of potential future outcomes. This gave more precise
                inferences, but the &#x2018;no unmeasured confounders&#x2019; assumption is highly
                questionable in this and other settings. Robins introduced a wide range of methods
                for equivalence trials based on the assumption of no unmeasured confounders [<xref ref-type="bibr" rid="bibr6-1740774510382439">6</xref>].</p>
      <p>An alternative approach by Walter <italic>et al</italic>. [<xref ref-type="bibr" rid="bibr7-1740774510382439">7</xref>] extended the approach of Sommer and Zeger
                    [<xref ref-type="bibr" rid="bibr26-1740774510382439">26</xref>] to a comparative
                trial with a binary outcome where participants might receive no treatment. They
                defined five principal strata [<xref ref-type="bibr" rid="bibr28-1740774510382439">28</xref>] by cross-classifying the treatment a participant would receive if
                randomized to A with the treatment they would receive if randomized to B. To
                identify the model, they made limited assumptions about comparability of principal
                strata, either constraining three relative risks to be equal or constraining two
                pairs of probabilities to be equal: the estimates may be sensitive to such
                assumptions, and external information is needed to justify them.</p>
      <p>Roy <italic>et al</italic>. [<xref ref-type="bibr" rid="bibr8-1740774510382439">8</xref>] identified causal effects in different principal strata without
                assuming either comparability between groups as treated or no unmeasured confounders
                    [<xref ref-type="bibr" rid="bibr8-1740774510382439">8</xref>]. However, their
                method assumed that potential outcomes were independent of covariates within
                principal strata, and this questionable assumption may have been the key to model
                identification.</p>
      <p>Our approach avoids making strong and typically unjustified assumptions, either
                comparability between groups as treated, possibly after covariate adjustment, or
                modeling assumptions. It accepts the likely nonidentifiability of the contrasts of
                interest from the observed data, and instead uses contextual or prior knowledge
                about the treatments.</p>
      <p>Is such prior knowledge likely to be available and reliable? In a comparative trial
                with some individuals receiving no treatment, we require prior knowledge about one
                of the treatment effects, or perhaps about some linear combination of the two
                treatment effects. This is very likely to be available from the literature, so we
                would often be able to use published trials or (ideally) meta-analyses to provide
                our prior knowledge. Even rather imprecise prior information is likely to be useful,
                and prior imprecision is unlikely to carry over substantially into the estimates of
                treatment contrasts unless nonreceipt of treatment is widespread and unbalanced.</p>
      <p>Greater difficulties may arise in the case of nontrial treatments, which may be new,
                untested or inadequately tested treatments. In this case expert opinions may be
                required. The analysis of the PENTA 5 trial presented here was part of a larger
                investigation of treatment changes throughout follow-up, which required priors for
                seven drugs from four classes. Even assuming common drug effects within classes,
                this was considered to be more information than could be obtained from the
                literature, since drug effects are likely to differ between children and adults, and
                few HIV trials have been done in children. Another difficulty with the use of expert
                prior information is deciding who should provide the prior. Ideally the prior would
                come from independent experts, but it will often more practically come from the
                trial investigators [<xref ref-type="bibr" rid="bibr32-1740774510382439">32</xref>].
                Clearly the prior must be stated so that it can be assessed by readers.</p>
      <p>Our methodology is a hybrid of instrumental variables and Bayesian methods. Purists
                will not like this, since full Bayesian methods require a full probability model
                while instrumental variables allows us to avoid this. However, we believe that our
                method combines the best aspects of both methodologies, using instrumental variables
                methods to avoid assumptions about the relationship between the dosage
                    <italic>D</italic> and the untreated outcome <italic>Y</italic>, and Bayesian
                methods to incorporate prior beliefs about nonprotocol parameters.</p>
      <p>Our results depend on the truth of the causal model. In PENTA 5, this assumed that
                the causal effect of a dose of drug was proportional to the dose received, and that
                there were no interactions between drugs. These assumptions are not easily checked
                from the data, since adding further terms to the causal model would only increase
                the number of nonidentified parameters on which prior information is needed.
                Therefore, sensitivity analyses are important [<xref ref-type="bibr" rid="bibr33-1740774510382439">33</xref>]. In PENTA 5, they could involve adding
                to the causal model <xref ref-type="disp-formula" rid="eq1-1740774510382439">
                    (1)</xref> nonlinear terms with assumed coefficient values. Estimation would
                then require expectations of these nonlinear terms to be computed as in <xref ref-type="disp-formula" rid="eq13-1740774510382439"> (13)</xref> and added into
                    <xref ref-type="disp-formula" rid="eq14-1740774510382439"> (14)</xref>.</p>
      <p>Our computational approach for the PENTA 5 data used Monte Carlo Markov Chain methods
                in WinBUGS. Computationally simpler approaches could be available; one idea might be
                to draw a small sample from the prior <italic>p</italic>(<bold>&#x3B1;</bold>),
                analyze the data conditionally on each value of <bold>&#x3B1;</bold>, and combine
                results as for multiply imputed data [<xref ref-type="bibr" rid="bibr34-1740774510382439">34</xref>].</p>
      <p>The methods presented here can also been extended to analyze longitudinal data, by
                replacing models <xref ref-type="disp-formula" rid="eq13-1740774510382439">
                    (13)</xref> and <xref ref-type="disp-formula" rid="eq14-1740774510382439">
                    (14)</xref> with time-dependent versions. This involves attention to the
                longitudinal error structure.</p>
      <p>Finally, our method in the simple case presented requires just knowledge of the mean
                receipt of each drug on each arm. Some information about treatment received is
                typically reported, but application of methods such as ours would be facilitated if
                treatment received were reported in a more standard way.</p>
    </sec>
  </body>
  <back>
    <ack>
      <title>Acknowledgments</title>
      <p content-type="acknowledgment">We thank the PENTA steering committee for allowing the use of the data from the PENTA
                5 trial, Sarah Walker for her help in eliciting prior beliefs, and our five experts
                for contributing their prior beliefs.</p>
    </ack>
    <sec id="sec20-1740774510382439">
      <title>Funding</title>
      <p content-type="funding">This work was supported by MRC grant U.1052.00.006.</p>
    </sec>
    <ref-list>
      <title>References</title>
      <ref id="bibr1-1740774510382439">
        <label>1</label>
        <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Pocock</surname><given-names>SJ</given-names></name></person-group><source>Clinical Trials: A Practical Approach</source>.
                        <publisher-name>Wiley</publisher-name>,
                        <publisher-loc>Chichester</publisher-loc>, <year>1983</year></mixed-citation>
      </ref>
      <ref id="bibr2-1740774510382439">
        <label>2</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Efron</surname><given-names>B</given-names></name><name><surname>Feldman</surname><given-names>D</given-names></name></person-group><article-title>Compliance as an explanatory variable in clinical
                        trials</article-title>. <source>J Am Stati Assoc</source><year>1991</year>; <volume>86</volume>:
                        <fpage>9</fpage>&#x2013;<lpage>17</lpage></mixed-citation>
      </ref>
      <ref id="bibr3-1740774510382439">
        <label>3</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>IR</given-names></name></person-group><article-title>Uses and limitations of randomization-based efficacy
                        estimators</article-title>. <source>Stat Methods Med Res</source><year>2005</year>; <volume>14</volume>:
                        <fpage>327</fpage>&#x2013;<lpage>47</lpage><pub-id pub-id-type="pmid">16178136</pub-id></mixed-citation>
      </ref>
      <ref id="bibr4-1740774510382439">
        <label>4</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Porta</surname><given-names>N</given-names></name><name><surname>Bonet</surname><given-names>C</given-names></name><name><surname>Cobo</surname><given-names>E</given-names></name></person-group><article-title>Discordance between reported intention-to-treat and per
                        protocol analyses</article-title>. <source>J Clin Epidemiol</source><year>2007</year>; <volume>60</volume>:
                        <fpage>663</fpage>&#x2013;<lpage>69</lpage><pub-id pub-id-type="pmid">17573981</pub-id></mixed-citation>
      </ref>
      <ref id="bibr5-1740774510382439">
        <label>5</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robins</surname><given-names>JM</given-names></name><name><surname>Greenland</surname><given-names>S</given-names></name></person-group><article-title>Adjusting for differential rates of prophylaxis therapy for
                        PCP in high-dose versus low-dose AZT treatment arms in an AIDS randomized
                        trial</article-title>. <source>J Am Stat Assoc</source><year>1994</year>; <volume>89</volume>:
                        <fpage>737</fpage>&#x2013;<lpage>49</lpage></mixed-citation>
      </ref>
      <ref id="bibr6-1740774510382439">
        <label>6</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robins</surname><given-names>JM</given-names></name></person-group><article-title>Correction for noncompliance in equivalence
                        trials</article-title>. <source>Stat Med</source><year>1998</year>; <volume>17</volume>:
                        <fpage>269</fpage>&#x2013;<lpage>302</lpage><pub-id pub-id-type="pmid">9493255</pub-id></mixed-citation>
      </ref>
      <ref id="bibr7-1740774510382439">
        <label>7</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walter</surname><given-names>SD</given-names></name><name><surname>Guyatt</surname><given-names>G</given-names></name><name><surname>Montori</surname><given-names>VM</given-names></name><etal/></person-group><article-title>A new preference-based analysis for randomized trials can
                        estimate treatment acceptability and effect in compliant
                        patients</article-title>. <source>J Clin Epidemiol</source><year>2006</year>; <volume>59</volume>:
                        <fpage>685</fpage>&#x2013;<lpage>96</lpage><pub-id pub-id-type="pmid">16765271</pub-id></mixed-citation>
      </ref>
      <ref id="bibr8-1740774510382439">
        <label>8</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roy</surname><given-names>J</given-names></name><name><surname>Hogan</surname><given-names>JW</given-names></name><name><surname>Marcus</surname><given-names>BH</given-names></name></person-group><article-title>Principal stratification with predictors of compliance for
                        randomized trials with 2 active treatments</article-title>.
                        <source>Biostatistics</source><year>2007</year>; <volume>9</volume>:
                        <fpage>277</fpage>&#x2013;<lpage>89</lpage><pub-id pub-id-type="pmid">17681993</pub-id></mixed-citation>
      </ref>
      <ref id="bibr9-1740774510382439">
        <label>9</label>
        <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Bernardo</surname><given-names>JM</given-names></name><name><surname>Smith</surname><given-names>AFM</given-names></name></person-group><source>Bayesian Theory</source>, <edition>2nd</edition><publisher-name>Wiley</publisher-name>,
                        <publisher-loc>Chichester</publisher-loc>, <year>2001</year></mixed-citation>
      </ref>
      <ref id="bibr10-1740774510382439">
        <label>10</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lunn</surname><given-names>DJ</given-names></name><name><surname>Thomas</surname><given-names>A</given-names></name><name><surname>Best</surname><given-names>N</given-names></name><name><surname>Spiegelhalter</surname><given-names>D</given-names></name></person-group><article-title>WinBUGS &#x2013; a Bayesian modeling framework: concepts,
                        structure, and extensibility</article-title>. <source>Stat Comput</source><year>2000</year>; <volume>10</volume>:
                        <fpage>325</fpage>&#x2013;<lpage>37</lpage></mixed-citation>
      </ref>
      <ref id="bibr11-1740774510382439">
        <label>11</label>
        <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Bowden</surname><given-names>RJ</given-names></name><name><surname>Turkington</surname><given-names>DA</given-names></name></person-group><source>Instrumental Variables</source>. <publisher-name>Cambridge
                        University Press</publisher-name>, <publisher-loc>Cambridge</publisher-loc>,
                        <year>1984</year></mixed-citation>
      </ref>
      <ref id="bibr12-1740774510382439">
        <label>12</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>B</given-names></name><name><surname>Jarvis</surname><given-names>P</given-names></name><name><surname>Lewis</surname><given-names>J</given-names></name><name><surname>Ebbutt</surname><given-names>A</given-names></name></person-group><article-title>Trials to assess equivalence: the importance of rigorous
                        methods</article-title>. <source>BMJ</source><year>1996</year>; <volume>313</volume>:
                        <fpage>36</fpage>&#x2013;<lpage>39</lpage><pub-id pub-id-type="pmid">8664772</pub-id></mixed-citation>
      </ref>
      <ref id="bibr13-1740774510382439">
        <label>13</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brittain</surname><given-names>E</given-names></name><name><surname>Lin</surname><given-names>D</given-names></name></person-group><article-title>A comparison of intent-to-treat and per-protocol results in
                        antibiotic noninferiority trials</article-title>. <source>Stat Med</source><year>2005</year>; <volume>24</volume>:
                        <fpage>1</fpage>&#x2013;<lpage>10</lpage><pub-id pub-id-type="pmid">15532089</pub-id></mixed-citation>
      </ref>
      <ref id="bibr14-1740774510382439">
        <label>14</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fleming</surname><given-names>TR</given-names></name></person-group><article-title>Current issues in noninferiority trials</article-title>.
                        <source>Stat Med</source><year>2008</year>; <volume>27</volume>:
                        <fpage>317</fpage>&#x2013;<lpage>32</lpage><pub-id pub-id-type="pmid">17340597</pub-id></mixed-citation>
      </ref>
      <ref id="bibr15-1740774510382439">
        <label>15</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubin</surname><given-names>D</given-names></name></person-group><article-title>Estimating causal effects of treatments in randomized and
                        non-randomized studies</article-title>. <source>J Educ Psychol</source><year>1974</year>; <volume>66</volume>:
                        <fpage>688</fpage>&#x2013;<lpage>701</lpage></mixed-citation>
      </ref>
      <ref id="bibr16-1740774510382439">
        <label>16</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bond</surname><given-names>SJ</given-names></name><name><surname>White</surname><given-names>IR</given-names></name><name><surname>Walker</surname><given-names>AS</given-names></name></person-group><article-title>Instrumental variables and interactions in the causal
                        analysis of a complex clinical trial</article-title>. <source>Stat
                        Med</source><year>2006</year>; <volume>26</volume>:
                        <fpage>1473</fpage>&#x2013;<lpage>96</lpage><pub-id pub-id-type="pmid">16900567</pub-id></mixed-citation>
      </ref>
      <ref id="bibr17-1740774510382439">
        <label>17</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robins</surname><given-names>JM</given-names></name></person-group><article-title>Correcting for noncompliance in randomized trials using
                        structural nested mean models</article-title>. <source>Commun Stat: Theor
                        Meth</source><year>1994</year>; <volume>23</volume>:
                        <fpage>2379</fpage>&#x2013;<lpage>2412</lpage></mixed-citation>
      </ref>
      <ref id="bibr18-1740774510382439">
        <label>18</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imbens</surname><given-names>GW</given-names></name><name><surname>Rubin</surname><given-names>DB</given-names></name></person-group><article-title>Bayesian inference for causal effects in randomized
                        experiments with noncompliance</article-title>. <source>Ann Statist</source><year>1997</year>; <volume>25</volume>:
                        <fpage>305</fpage>&#x2013;<lpage>27</lpage></mixed-citation>
      </ref>
      <ref id="bibr19-1740774510382439">
        <label>19</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>AS</given-names></name><name><surname>White</surname><given-names>IR</given-names></name><name><surname>Babiker</surname><given-names>AG</given-names></name></person-group><article-title>Parametric randomization-based methods for correcting for
                        treatment changes in the assessment of the causal effect of
                        treatment</article-title>. <source>Stat Med</source><year>2004</year>; <volume>23</volume>:
                        <fpage>571</fpage>&#x2013;<lpage>90</lpage><pub-id pub-id-type="pmid">14755390</pub-id></mixed-citation>
      </ref>
      <ref id="bibr20-1740774510382439">
        <label>20</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goetghebeur</surname><given-names>E</given-names></name><name><surname>Lapp</surname><given-names>K</given-names></name></person-group><article-title>The effect of treatment compliance in a placebocontrolled
                        trial: Regression with unpaired data</article-title>. <source>J R Stat Soc
                        Ser C</source><year>1997</year>; <volume>46</volume>:
                        <fpage>351</fpage>&#x2013;<lpage>64</lpage></mixed-citation>
      </ref>
      <ref id="bibr21-1740774510382439">
        <label>21</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fischer</surname><given-names>K</given-names></name><name><surname>Goetghebeur</surname><given-names>E</given-names></name></person-group><article-title>Practical properties of some structural mean analyses of the
                        effect of compliance in randomized trials</article-title>. <source>Control
                        Clin Trials</source><year>1999</year>; <volume>20</volume>:
                        <fpage>531</fpage>&#x2013;<lpage>46</lpage><pub-id pub-id-type="pmid">10588294</pub-id></mixed-citation>
      </ref>
      <ref id="bibr22-1740774510382439">
        <label>22</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fischer</surname><given-names>K</given-names></name><name><surname>Goetghebeur</surname><given-names>E</given-names></name><name><surname>Vrijens</surname><given-names>B</given-names></name><name><surname>White</surname><given-names>IR</given-names></name></person-group><article-title>A structural mean model to analyze the effect of compliance
                        when comparing two active treatments</article-title>.
                        <source>Biostatistics</source><comment>(in press)</comment></mixed-citation>
      </ref>
      <ref id="bibr23-1740774510382439">
        <label>23</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oakley</surname><given-names>JE</given-names></name><name><surname>O'Hagan</surname><given-names>A</given-names></name></person-group><article-title>Probabilistic sensitivity analysis of complex models: a
                        Bayesian approach</article-title>. <source>J R Stat Soc Ser B</source><year>2004</year>; <volume>66</volume>:
                        <fpage>751</fpage>&#x2013;<lpage>69</lpage></mixed-citation>
      </ref>
      <ref id="bibr24-1740774510382439">
        <label>24</label>
        <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>O'Hagan</surname><given-names>A</given-names></name><name><surname>Buck</surname><given-names>CE</given-names></name><name><surname>Daneshkhah</surname><given-names>A</given-names></name><etal/></person-group><source>Uncertain Judgements: Eliciting Expert Probabilities</source>.
                        <publisher-name>Wiley</publisher-name>,
                        <publisher-loc>Chichester</publisher-loc>, <year>2006</year></mixed-citation>
      </ref>
      <ref id="bibr25-1740774510382439">
        <label>25</label>
        <mixed-citation publication-type="book">
          <comment><bold>Paediatric European Network for
                            Treatment of AIDS</bold>. Comparison of dual nucleoside-analogue
                        reverse-transcriptase inhibitor regimes with and without nelfinavir in
                        children with HIV-1 who have not previously been treated: the PENTA 5
                        randomized trial. <italic>Lancet</italic> 2002; 359:
                        733&#x2013;40</comment>
        </mixed-citation>
      </ref>
      <ref id="bibr26-1740774510382439">
        <label>26</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sommer</surname><given-names>A</given-names></name><name><surname>Zeger</surname><given-names>SL</given-names></name></person-group><article-title>On estimating efficacy from clinical trials</article-title>.
                        <source>Stat Med</source><year>1991</year>; <volume>10</volume>:
                        <fpage>45</fpage>&#x2013;<lpage>52</lpage><pub-id pub-id-type="pmid">2006355</pub-id></mixed-citation>
      </ref>
      <ref id="bibr27-1740774510382439">
        <label>27</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Angrist</surname><given-names>JD</given-names></name><name><surname>Imbens</surname><given-names>GW</given-names></name><name><surname>Rubin</surname><given-names>DB</given-names></name></person-group><article-title>Identification of causal effects using instrumental
                        variables</article-title>. <source>J Am Stat Assoc</source><year>1996</year>; <volume>91</volume>:
                        <fpage>444</fpage>&#x2013;<lpage>72</lpage></mixed-citation>
      </ref>
      <ref id="bibr28-1740774510382439">
        <label>28</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frangakis</surname><given-names>CE</given-names></name><name><surname>Rubin</surname><given-names>DB</given-names></name></person-group><article-title>Principal stratification in causal inference</article-title>.
                        <source>Biometrics</source><year>2002</year>; <volume>58</volume>:
                        <fpage>21</fpage>&#x2013;<lpage>29</lpage><pub-id pub-id-type="pmid">11890317</pub-id></mixed-citation>
      </ref>
      <ref id="bibr29-1740774510382439">
        <label>29</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cuzick</surname><given-names>J</given-names></name><name><surname>Edwards</surname><given-names>R</given-names></name><name><surname>Segnan</surname><given-names>N</given-names></name></person-group><article-title>Adjusting for noncompliance and contamination in randomized
                        clinical trials</article-title>. <source>Stat Med</source><year>1997</year>; <volume>16</volume>:
                        <fpage>1017</fpage>&#x2013;<lpage>29</lpage><pub-id pub-id-type="pmid">9160496</pub-id></mixed-citation>
      </ref>
      <ref id="bibr30-1740774510382439">
        <label>30</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirano</surname><given-names>K</given-names></name><name><surname>Imbens</surname><given-names>GW</given-names></name><name><surname>Rubin</surname><given-names>DB</given-names></name><name><surname>Zhou</surname><given-names>XH</given-names></name></person-group><article-title>Assessing the effect of an influenza vaccine in an
                        encouragement design</article-title>. <source>Biostatistics</source><year>2000</year>; <volume>1</volume>:
                        <fpage>69</fpage>&#x2013;<lpage>88</lpage><pub-id pub-id-type="pmid">12933526</pub-id></mixed-citation>
      </ref>
      <ref id="bibr31-1740774510382439">
        <label>31</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barnard</surname><given-names>J</given-names></name><name><surname>Frangakis</surname><given-names>CE</given-names></name><name><surname>Hill</surname><given-names>JL</given-names></name><name><surname>Rubin</surname><given-names>DB</given-names></name></person-group><article-title>Principal stratification approach to broken randomized
                        experiments: A case study of school choice vouchers in New York
                        City</article-title>. <source>J Am Stat Assoc</source><year>2003</year>; <volume>98</volume>:
                        <fpage>299</fpage>&#x2013;<lpage>311</lpage></mixed-citation>
      </ref>
      <ref id="bibr32-1740774510382439">
        <label>32</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>IR</given-names></name><name><surname>Carpenter</surname><given-names>J</given-names></name><name><surname>Evans</surname><given-names>S</given-names></name><name><surname>Schroter</surname><given-names>S</given-names></name></person-group><article-title>Eliciting and using expert opinions about non-response bias
                        in randomised controlled trials</article-title>. <source>Clin
                        Trials</source><year>2007</year>; <volume>4</volume>:
                        <fpage>125</fpage>&#x2013;<lpage>39</lpage><pub-id pub-id-type="pmid">17456512</pub-id></mixed-citation>
      </ref>
      <ref id="bibr33-1740774510382439">
        <label>33</label>
        <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vansteelandt</surname><given-names>S</given-names></name><name><surname>Goetghebeur</surname><given-names>E</given-names></name></person-group><article-title>Sense and sensitivity when correcting for observed exposures
                        in randomized clinical trials</article-title>. <source>Stat Med</source><year>2005</year>; <volume>24</volume>:
                        <fpage>191</fpage>&#x2013;<lpage>210</lpage><pub-id pub-id-type="pmid">15515152</pub-id></mixed-citation>
      </ref>
      <ref id="bibr34-1740774510382439">
        <label>34</label>
        <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Rubin</surname><given-names>DB</given-names></name></person-group><source>Multiple Imputation for Nonresponse in Surveys</source>.
                        <publisher-name>John Wiley and Sons</publisher-name>, <publisher-loc>New
                        York</publisher-loc>, <year>1987</year></mixed-citation>
      </ref>
      <ref id="bibr35-1740774510382439">
        <label>35</label>
        <mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Golub</surname><given-names>GH</given-names></name><name><surname>Van
                                Loan</surname><given-names>CF</given-names></name></person-group><source>Matrix Computations</source>, <edition>2nd</edition><publisher-name>Johns Hopkins University Press</publisher-name>,
                        <publisher-loc>Baltimore</publisher-loc>, <year>1989</year></mixed-citation>
      </ref>
    </ref-list>
    <app-group>
      <app id="app1-1740774510382439">
        <title>Appendices</title>
        <p>
          <bold>(A) Information sheet for elicitees</bold>
        </p>
        <p>Randomized control trial prior elicitation</p>
        <p>You will shortly be asked for your opinion on the results of a sequence of
                    hypothetical RCTs. These trials all have recruitment criteria that are identical
                    to those used in the PENTA-5 trial (children aged 3 months to 16 years, HIV-1
                    infection, no previous anti-retroviral treatment and without transmitted drug
                    resistance). They only differ in the combinations of drugs to be compared in the
                    two arms. For example, in question 1, the trial consists of two arms; arm A
                    (3TC+ABC+PI) versus arm B (ABC+NRTI+PI), and the
                    outcome is change in log<sub>10</sub> RNA measurement from baseline to 48
                    weeks.</p>
        <p>The end result of the trial is the mean difference (arm A &#x2212; arm B)
                    between these changes from baseline in the two randomized groups. So for
                    example, if there was a 2.5 log drop in arm A, and a 3.0 log drop in arm B, the
                    mean difference between arms would be
                    +0.5&#x2009;=&#x2009;&#x2212;2.5&#x2009;&#x2212;&#x2009;&#x2212;3.0.
                    Call this quantity, X: X is unknown, but in your expert opinion there are some
                    values that are more likely than others.</p>
        <p>A potential &#x2018;best guess&#x2019; for X is the point whereby you believe
                    that 50% of the time the X you actually observed in a RCT would be less
                    than this cut-point, and 50% of the time it would be larger: this would
                    be the median X observed if we carried out a large number of trials. This median
                    would be the cut-point whereby you would be ambivalent between accepting a bet,
                    or placing a bet, on the event that the X observed in one trial would be larger
                    than this.</p>
        <p>Mark on the line of your expert opinion on this value, the median. If you think B
                    is a better regimen than A, this value should be positive, the right-hand side
                    of the line. If you think A is better it should be negative, the left-hand side
                    of the line. For clarity please annotate the mark with the letter
                    &#x2018;M&#x2019;.</p>
        <p>Now, imagine that X has been observed in an RCT and you are told that its value
                    is greater than the value you have marked for the median &#x2013; that is, a
                    RCT has shown that B is actually better than you thought it was. Conditional on
                    this extra knowledge, mark your &#x2018;best guess&#x2019; at the revised
                    median on the same line. <italic>This mark should always be to the right of your
                        first mark</italic> &#x2013; B is better than you thought it was.</p>
        <p>Finally, you are now told that another trial has observed an X even greater than
                    the value you have just marked , so that B is even better than your second
                    guess: mark your &#x2018;best guess&#x2019; at the revised median.
                        <italic>This mark should always be to the right of your first two
                        marks</italic> &#x2013; B is even better than you thought it was.</p>
        <p>This exercise is now repeated for another 21 hypothetical trials that have the
                    same outcome measure and recruitment procedure, but differ in the treatment
                    assigned in the two arms. Where the randomized comparison is between a class and
                    a specific drug (e.g., 3TC vs. NRTI in the first example), please assume that
                    the clinician has a free choice amongst drugs of that class, and is likely to
                    prescribe according to current clinical practice.</p>
      </app>
      <app id="app2-1740774510382439">
        <title>(B) Visual analog scale</title>
        <p>
          <fig id="fig3-1740774510382439" position="anchor">
            <graphic xlink:href="10.1177_1740774510382439-fig3"/>
          </fig>
        </p>
      </app>
      <app id="app3-1740774510382439">
        <title>(C) WinBUGS code</title>
        <p>
          <fig id="fig4-1740774510382439" position="anchor">
            <graphic xlink:href="10.1177_1740774510382439-fig4"/>
            <graphic xlink:href="10.1177_1740774510382439-fig4a"/>
            <graphic xlink:href="10.1177_1740774510382439-fig4b"/>
          </fig>
        </p>
      </app>
      <app id="app4-1740774510382439">
        <title>(D) Independent prior</title>
        <p>Let the <italic>g</italic>&#x2009;&#x2212;&#x2009;1 protocol contrasts and the
                        <italic>p</italic>&#x2009;&#x2212;&#x2009;<italic>g</italic>&#x2009;+&#x2009;1
                    nonprotocol contrasts be expressed as
                            <bold>&#x3B1;</bold><sub><italic>p</italic></sub>&#x2009;=&#x2009;<bold><italic>L</italic></bold><sub><italic>p</italic></sub>
                    <bold>&#x3B1;</bold> and
                            <bold>&#x3B1;</bold><sub><italic>n</italic></sub>&#x2009;=&#x2009;<bold><italic>L</italic></bold><sub><italic>n</italic></sub><bold><italic>&#x3B1;</italic></bold>,
                    respectively, where <bold><italic>L</italic></bold><sub><italic>p</italic></sub>
                    is a
                        (<italic>g</italic>&#x2009;&#x2212;&#x2009;1)&#x2009;&#xD7;&#x2009;<italic>p</italic>
                    matrix and <bold><italic>L</italic></bold><sub><italic>n</italic></sub> is a
                        (<italic>p</italic>&#x2009;&#x2212;&#x2009;<italic>g</italic>&#x2009;+&#x2009;1)&#x2009;&#xD7;&#x2009;<italic>p</italic>
                    matrix. Let the full prior for <italic>p</italic>-dimensional
                        <bold>&#x3B1;</bold> be multivariate normal with covariance matrix
                    &#x3A3;.</p>
        <p>We argued in the section &#x2018;Obtaining prior information&#x2019; that
                        <bold>&#x3B1;</bold><sub><italic>n</italic></sub> should be independent of
                        <bold>&#x3B1;</bold><sub><italic>p</italic></sub> in the prior, so we must
                    find <bold><italic>L</italic></bold><sub><italic>n</italic></sub> that solves <inline-formula><mml:math id="ilm24-1740774510382439"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">L</mml:mi></mml:mrow><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mi>&#x3A3;</mml:mi><mml:msubsup><mml:mrow><mml:mi mathvariant="bold-italic">L</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mo>'</mml:mo></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mo>.</mml:mo></mml:mrow></mml:math></inline-formula>
                    This can be done by finding the <bold>QR</bold> decomposition [<xref ref-type="bibr" rid="bibr35-1740774510382439">35</xref>, section 5.2] of <inline-formula><mml:math id="ilm25-1740774510382439"><mml:mrow><mml:mi>&#x3A3;</mml:mi><mml:msubsup><mml:mrow><mml:mi mathvariant="bold-italic">L</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mo>&#x2032;</mml:mo></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mi mathvariant="bold-italic">QR,</mml:mi></mml:mrow></mml:math></inline-formula> which computes the
                        <italic>p</italic>&#x2009;&#xD7;&#x2009;<italic>p</italic> orthogonal
                    matrix <bold><italic>Q</italic></bold>, and the
                        <italic>p</italic>&#x2009;&#xD7;&#x2009;(<italic>g</italic>&#x2009;&#x2212;&#x2009;1)
                    matrix <bold><italic>R</italic></bold>, with zero elements apart from the first
                        <italic>g</italic>&#x2009;&#x2212;&#x2009;1 rows that form an upper
                    triangular matrix. Pre-multiplying by <bold><italic>Q</italic></bold>&#x2032;
                    shows that the last
                        <italic>p</italic>&#x2009;&#x2212;&#x2009;<italic>g</italic>&#x2009;+&#x2009;1
                    rows of <bold><italic>Q</italic></bold>&#x2032; provide a solution.</p>
        <p>For the PENTA 5 prior distribution expressed in <xref ref-type="table" rid="table4-1740774510382439">Table 4</xref>, this procedure gives the two
                    components of <bold>&#x3B1;</bold><sub><italic>n</italic></sub> as
                        0.806&#x3B1;<sub>1</sub>&#x2009;+&#x2009;0.413&#x3B1;<sub>2</sub>&#x2009;+&#x2009;0.687&#x3B1;<sub>3</sub>&#x2009;+&#x2009;0.012&#x3B1;<sub>4</sub>,
                    roughly representing an average effect of the three trial treatments, and
                        &#x2212;0.046&#x3B1;<sub>1</sub>&#x2009;&#x2212;&#x2009;0.088&#x3B1;<sub>2</sub>&#x2009;+&#x2009;0.176&#x3B1;<sub>3</sub>&#x2009;+&#x2009;0.985&#x3B1;<sub>4</sub>,
                    roughly representing the effect of the nontrial treatment.</p>
      </app>
    </app-group>
  </back>
</article>
